Finding the right dose of a new combo for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new three-drug combination for advanced head and neck cancer that cannot be cured by local treatments. It aims to find the best dose of a targeted therapy called Zanzalintinib when given with two standard immunotherapy and targeted drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced head and neck squamous cell cancer that has come back or spread and cannot be cured by surgery or radiation.
- Your tumor started in the throat, mouth, voice box, nasal cavity, or sinuses—or the origin is unknown.
- You are at least 18 years old and able to get around and care for yourself (ECOG score 0 or 1).
- You have not had more than 2 prior treatments for cancer that came back or spread.
- You have not received cetuximab or certain other targeted therapies before.
- Your cancer can be measured on scans, and your blood counts and organ function are adequate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.
This trial studies an experimental drug called zanzalintinib for people with adenoid cystic carcinoma that has spread or come back. The goal is to see if the drug can shrink tumors or slow the disease.
This trial tests a new combination of two drugs (telisotuzumab adizutecan and pembrolizumab) for people with head and neck cancer that has come back or spread and cannot be cured with local treatments. The goal is to see if this combination can help control the cancer and to find the best dose.
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
This trial tests a new drug combination for people with advanced clear cell kidney cancer that has gotten worse after initial immunotherapy treatment. The goal is to see if adding zanzalintinib to another immunotherapy can help control the cancer.
This trial tests new drug combinations for people with advanced kidney cancer whose disease returned after a prior immunotherapy. It's designed to find better treatment options for those who have not received other treatments for advanced disease.
Hear when a new Head and Neck Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.